New medicine for two types of pulmonary fibrosis
EMA has recommended granting a marketing authorisation in the European Union (EU) for Jascayd (nerandomilast) to treat adults with idiopathic pulmonary fibrosis (IPF) or…
EMA has recommended granting a marketing authorisation in the European Union (EU) for Jascayd (nerandomilast) to treat adults with idiopathic pulmonary fibrosis (IPF) or…
Read the full article at the source
Need general health in Europe?
Browse verified clinics with transparent pricing and real reviews across 30+ countries.
Source.
European Medicines Agency — European Medicines Agency, CC BY 4.0
Medical disclaimer.
Articles are general information aggregated from third-party medical sources. They are NOT a substitute for in-person diagnosis or treatment. For personal medical guidance, consult a verified clinician or call your local emergency line (112 in the EU).